202 related articles for article (PubMed ID: 34220581)
21. Potential involvement of serotonergic signaling in ketamine's antidepressant actions: A critical review.
du Jardin KG; Müller HK; Elfving B; Dale E; Wegener G; Sanchez C
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Nov; 71():27-38. PubMed ID: 27262695
[TBL] [Abstract][Full Text] [Related]
22. Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depression.
Jesus-Nunes AP; Leal GC; Correia-Melo FS; Vieira F; Mello RP; Caliman-Fontes AT; Echegaray MVF; Marback RF; Guerreiro-Costa LNF; Souza-Marques B; Santos-Lima C; Souza LS; Bandeira ID; Kapczinski F; Lacerda ALT; Quarantini LC
Hum Psychopharmacol; 2022 Jul; 37(4):e2836. PubMed ID: 35179810
[TBL] [Abstract][Full Text] [Related]
23. Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion.
Pennybaker SJ; Niciu MJ; Luckenbaugh DA; Zarate CA
J Affect Disord; 2017 Jan; 208():560-566. PubMed ID: 27839782
[TBL] [Abstract][Full Text] [Related]
24. Magnetoencephalographic Correlates of Suicidal Ideation in Major Depression.
Gilbert JR; Ballard ED; Galiano CS; Nugent AC; Zarate CA
Biol Psychiatry Cogn Neurosci Neuroimaging; 2020 Mar; 5(3):354-363. PubMed ID: 31928949
[TBL] [Abstract][Full Text] [Related]
25. Fine-tuning neural excitation/inhibition for tailored ketamine use in treatment-resistant depression.
Fagerholm ED; Leech R; Williams S; Zarate CA; Moran RJ; Gilbert JR
Transl Psychiatry; 2021 May; 11(1):335. PubMed ID: 34052834
[TBL] [Abstract][Full Text] [Related]
26. Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.
Niciu MJ; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Furey ML; Zarate CA
Int J Neuropsychopharmacol; 2014 Oct; 18(1):. PubMed ID: 25539512
[TBL] [Abstract][Full Text] [Related]
27. Effects of GRIN2B , GRIA1 , and BDNF Polymorphisms on the Therapeutic Action of Ketamine and Esketamine in Treatment-Resistant Depression Patients: Secondary Analysis From a Randomized Clinical Trial.
Beanes G; Caliman-Fontes AT; Souza-Marques B; Silva HDS; Leal GC; Carneiro BA; Guerreiro-Costa LNF; Figueiredo AV; Figueiredo CAV; Lacerda ALT; Costa RDS; Quarantini LC
Clin Neuropharmacol; 2022 Nov-Dec 01; 45(6):151-156. PubMed ID: 36093918
[TBL] [Abstract][Full Text] [Related]
28. Neural correlates of rapid antidepressant response to ketamine in bipolar disorder.
Nugent AC; Diazgranados N; Carlson PJ; Ibrahim L; Luckenbaugh DA; Brutsche N; Herscovitch P; Drevets WC; Zarate CA
Bipolar Disord; 2014 Mar; 16(2):119-28. PubMed ID: 24103187
[TBL] [Abstract][Full Text] [Related]
29. Ketamine-induced changes in resting state connectivity, 2 h after the drug administration in patients with remitted depression.
Burrows M; Kotoula V; Dipasquale O; Stringaris A; Mehta MA
J Psychopharmacol; 2023 Aug; 37(8):784-794. PubMed ID: 37491833
[TBL] [Abstract][Full Text] [Related]
30. Prolonged ketamine infusion modulates limbic connectivity and induces sustained remission of treatment-resistant depression.
Siegel JS; Palanca BJA; Ances BM; Kharasch ED; Schweiger JA; Yingling MD; Snyder AZ; Nicol GE; Lenze EJ; Farber NB
Psychopharmacology (Berl); 2021 Apr; 238(4):1157-1169. PubMed ID: 33483802
[TBL] [Abstract][Full Text] [Related]
31. Magnetoencephalography biomarkers of suicide attempt history and antidepressant response to ketamine in treatment-resistant major depression.
Gilbert JR; Gerner JL; Burton CR; Nugent AC; Zarate CA; Ballard ED
J Affect Disord; 2022 Sep; 312():188-197. PubMed ID: 35728680
[TBL] [Abstract][Full Text] [Related]
32. Lithium and Valproate Levels Do Not Correlate with Ketamine's Antidepressant Efficacy in Treatment-Resistant Bipolar Depression.
Xu AJ; Niciu MJ; Lundin NB; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Machado-Vieira R; Zarate CA
Neural Plast; 2015; 2015():858251. PubMed ID: 26137324
[TBL] [Abstract][Full Text] [Related]
33. Ketamine improves short-term plasticity in depression by enhancing sensitivity to prediction errors.
Sumner RL; McMillan R; Spriggs MJ; Campbell D; Malpas G; Maxwell E; Deng C; Hay J; Ponton R; Sundram F; Muthukumaraswamy SD
Eur Neuropsychopharmacol; 2020 Sep; 38():73-85. PubMed ID: 32763021
[TBL] [Abstract][Full Text] [Related]
34. Lithium continuation therapy following ketamine in patients with treatment resistant unipolar depression: a randomized controlled trial.
Costi S; Soleimani L; Glasgow A; Brallier J; Spivack J; Schwartz J; Levitch CF; Richards S; Hoch M; Stade EC; Welch A; Collins KA; Feder A; Iosifescu DV; Charney DS; Murrough JW
Neuropsychopharmacology; 2019 Sep; 44(10):1812-1819. PubMed ID: 30858518
[TBL] [Abstract][Full Text] [Related]
35. Antidepressant Effect of Ketamine on Inflammation-Mediated Cytokine Dysregulation in Adults with Treatment-Resistant Depression: Rapid Systematic Review.
Sukhram SD; Yilmaz G; Gu J
Oxid Med Cell Longev; 2022; 2022():1061274. PubMed ID: 36160713
[TBL] [Abstract][Full Text] [Related]
36. Efficacy, Safety, and Durability of Repeated Ketamine Infusions for Comorbid Posttraumatic Stress Disorder and Treatment-Resistant Depression.
Albott CS; Lim KO; Forbes MK; Erbes C; Tye SJ; Grabowski JG; Thuras P; Batres-Y-Carr TM; Wels J; Shiroma PR
J Clin Psychiatry; 2018; 79(3):. PubMed ID: 29727073
[TBL] [Abstract][Full Text] [Related]
37. Ketamine: The final frontier or another depressing end?
Sial OK; Parise EM; Parise LF; Gnecco T; Bolaños-Guzmán CA
Behav Brain Res; 2020 Apr; 383():112508. PubMed ID: 32017978
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.
Dwyer JB; Landeros-Weisenberger A; Johnson JA; Londono Tobon A; Flores JM; Nasir M; Couloures K; Sanacora G; Bloch MH
Focus (Am Psychiatr Publ); 2022 Apr; 20(2):241-251. PubMed ID: 37153136
[TBL] [Abstract][Full Text] [Related]
39. The Relationship Between Acute Dissociative Effects Induced by Ketamine and Treatment Response in Adolescent Patients with Treatment-Resistant Depression.
Lineham A; Avila-Quintero VJ; Bloch MH; Dwyer J
J Child Adolesc Psychopharmacol; 2023 Feb; 33(1):20-26. PubMed ID: 36799961
[No Abstract] [Full Text] [Related]
40. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Murrough JW; Iosifescu DV; Chang LC; Al Jurdi RK; Green CE; Perez AM; Iqbal S; Pillemer S; Foulkes A; Shah A; Charney DS; Mathew SJ
Am J Psychiatry; 2013 Oct; 170(10):1134-42. PubMed ID: 23982301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
